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Abstract 530 – Table 1. Characteristics of Individual Trials included in Meta-analysis
1st author, year No. patients Mean (SD) age of No. (%) women Mean (SD) BMI of Minimum JSW at baseline
randomized patients randomized randomized patients randomized in patients randomized
to CS/placebo to CS/placebo to CS/placebo to CS/placebo to CS/placebo
Michel, 2005 150/150 62.5 (9.1)/63.1 (10.7) 76 (51)/78 (52) 27.7 (5.2)/28.1 (5.5) 2.41 (0.14)/2.35 (0.14)
Sawitzke, 2008 123/134 (only 71/70 were assessable) 56.4 (9.2)/56.6 (8.4) 51 (72)/45 (64) NS/NS 3.86 (0.90)/4.07 (0.93)
Kahan, 2009 309/313 62.9 (0.5)/61.8 (0.5) 216 (70)/209 (67) 28.5 (0.4)/29.0 (0.4) 3.73 (0.08)/3.81 (0.07)
data from the intention-to-treat populations for pooling. Results
were summarized for both the absolute difference between the
chondroitin sulfate and placebo-treated groups as well as the
standardized effect size using the pooled standard deviations.
Fixed effects models were used as the I2 statistic showed no evi-
dence of between-trial heterogeneity. All analyses were perfomred
using RevMan version 5 software (www.cc-ims.net).
Results: Results from 3 randomized placebo-controlled trials of 2
years duration were included in this pooled analysis; characteris-
tics of the individual trials are shown in the Table. Overall, data
from 530 patients who were randomized to chondroitin sulfate at
a dose of 800 mg/day and 533 patients who were randomized to
placebo were included in the pooled analysis. The pooled mean
difference in decline in minimum tibiofemoral joint space width over
2 years was 0.13 mm (95% conﬁdence intervals [CI] 0.06, 0.19)
less in the chondroitin sulfate treated groups compared to the
placebo treated groups (P = 0.0002). This difference corresponds
to an effect size of 0.23 (95% CI 0.11, 0.35) (P = 0.0002).
Conclusions: These data demonstrate that chondroitin sulfate at
a dose of 800 mg/day is effective for reducing the rate of decline in
minimum medial tibiofemoral joint space width in patients with knee
OA over 2 years. These results support OARSI recommendations
for the use of chondroitin sulfate as a structure-modifying agent
for patients with knee OA.
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ANTI-INFLAMMATORY EFFECTS AND GASTROINTESTINAL
SAFETY OF THE CYCLOOXYGENASE-INHIBITING NITRIC
OXIDE DONATOR (CINOD) HCT 1026
S. Viappiani1, P. Pﬁster1, J. Raud2, M. Bolla1
1NicOx R&D, Sophia-Antipolis, France; 2AstraZeneca, Sodertalje,
Sweden
Purpose: Long-term use of non steroidal anti-inﬂammatory drugs
(NSAIDs) for the treatment of inﬂammatory conditions such as
osteoarthritis is hampered by gastrointestinal (GI) side effects
and increased potential for cardiovascular events. HCT 1026 is a
cyclooxygenase-inhibiting nitric oxide donator (CINOD) providing
balanced cyclooxygenases inhibition along with the release of nitric
oxide (NO). Through NO donation, HCT 1026 may offer improved
tolerability over traditional NSAIDs, potentially by mitigating the
detrimental effects caused by prostaglandin suppression. The
aim of this study is to characterize the anti-inﬂammatory activity,
gastrointestinal tolerability and in vivo NO release of HCT 1026, a
ﬂurbiprofen-based CINOD, in animal models
Methods: Pleural inﬂammation was induced in anaesthetised
Sprague-Dawley rats by injection of 1% carrageenan into the
thoracic cavity. Animals were euthanized 4h later and thoracic
exudates collected for determination of volume and leukocyte in-
ﬁltration. HCT 1026, ﬂurbiprofen (both at 12.5 and 50 μmol/kg)
or vehicle were administered by gavage 1h prior to carrageenan
injection. GI tolerability was assessed in rats treated twice daily
with vehicle or 40 μmol/kg HCT 1026 or ﬂurbiprofen and sacriﬁced
after 5-7 days for determination of stomach and ileum damage
(presence of ulcers, adhesions and ileum damage score in mm).
In vivo NO donation was tested in New Zealand rabbits previously
anaesthetised, ventilated, and cannulated in the carotid artery for
blood pressure (BP) measurement. Animals were treated with 30
mg/kg L-NAME to quench endogenous NO production and HCT
1026 or ﬂurbiprofen (100 μmol/kg in 6 min, infusion in the jugular
vein) or vehicle (DMSO) were administered following a cross-over
protocol (1 h wash out)
Results: HCT 1026 (12.5 and 50 μmol/kg) dose-dependently in-
hibited carrageenan-induced pleural ﬂuid accumulation (46 and 61
% reduction vs. control, respectively) and neutrophil inﬁltration (22
and 48% reduction vs. control, respectively), similar to equimolar
doses of ﬂurbiprofen.
Administration of 40 μmol/kg HCT 1026 for 7 days was well
tolerated and caused only a slight reduction in haematocrit (8%
decrease vs. vehicle), while administration of an equimolar amount
of ﬂurbiprofen strikingly decreased haematocrit (25% vs. vehicle),
causing death of almost all animals before the end of the study.
Analysis of the GI tract at sacriﬁce revealed no gastric ulcers
in HCT 1026-treated animals, with adhesions in 2 out of 10
animals and minimal ileum damage (0.2±0.1 mm). In contrast,
ﬂurbiprofen caused gastric ulcers in 2 out of 9 animals, adhesions
in all animals, and extensive ileum damage (21.4±3.6 mm).In
rabbits pretreated with L-NAME, infusion of HCT 1026 resulted
in a moderate signiﬁcant increase in exhaled NO (from 0.4±0.15
to 2.3±0.4 ppb) which lasted up to 60 min, and a reduction of
BP of ∼21 cmH2O (15.5 mmHg). Flurbiprofen did not alter these
parameters
Conclusions:HCT 1026 displays effective anti-inﬂammatory prop-
erties comparable to the reference NSAID ﬂurbiprofen in the
pleurisy model, with a superior GI tolerability proﬁle, likely due to
its ability to donate NO (as observed in vivo)
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GASTROINTESTINAL SAFETY OF THE
CYCLOOXYGENASE-INHIBITING NITRIC OXIDE DONATOR
(CINOD) HCT 2037 IN A RAT MODEL OF INFLAMMATION
S. Viappiani1, J.L. Wallace2, M. Bolla1
1NicOx SA, Sophia-Antipolis, France; 2McMaster Univ., Hamilton,
ON, Canada
Purpose: Chronic treatment of osteoarthritis with non steroidal
anti-inﬂammatory drugs (NSAIDs) is associated with several
gastro-intestinal (GI) side effects. In addition, increased cardio-
vascular risk has been documented following their long-term use.
Cyclooxygenase-inhibiting nitric oxide donators (CINODs) bear
both COX-1 and COX-2-inhibiting activity as well as nitric oxide
(NO) donating properties. The rationale behind this approach is
to increase GI tolerability while retaining the anti-inﬂammatory
properties typical of NSAIDs. Here, we present the GI safety pro-
ﬁle of HCT 2037, a ketoprofen-based CINOD, in a rat model of
inﬂammation.
Methods: Efﬁcacy and gastric damage were evaluated in parallel
in the carrageenan-induced model of inﬂammation. Male Wistar
rats were orally administered 0.3-35.7 mg/kg HCT 2037 or equimo-
lar doses of ketoprofen 30 min before carrageenan injection into
the right paw. Edema was measured at regular times for further
5 h. Rats were then euthanized and the stomachs excised and
analyzed to assess gastric damage score (sum in mm of all hem-
orrhagic erosions). UD30 and ED30 were calculated as the doses
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causing 30% of ulcer incidence and 30% of maximal efﬁcacy,
respectively. The plasma concentrations of ketoprofen after oral
administration of HCT 2037 (7.1 and 10.7 mg/kg) or equimolar
ketoprofen were assessed in separate male Sprague Dawley rats
using a HPLC MS/MS technique.
Results: HCT 2037 signiﬁcantly and dose-dependently decreased
paw edema formation. The highest dose tested (35.7 mg/kg) re-
duced edema formation by 59±6% vs. control (p<0.01) and the
ED30 was estimated to be 7.1 mg/kg, with a UD30 of 3.0 mg/kg.
The reference ketoprofen showed a 4-fold lower activity in inhibit-
ing edema formation (ED30>25 mg/kg), and caused marked GI
damage, with a UD30 of 1.3 mg/kg. By comparing ED30/UD30
ratios, HCT 2037 emerged as a more favourable compound than
ketoprofen (2.4 vs. >18.9, respectively). Pharmacokinetic analy-
sis following oral administration to rats of equimolar doses HCT
2037 or ketoprofen revealed that animals were exposed to similar
plasma concentrations of ketoprofen.
Conclusions: HCT 2037 showed a tendency towards a better ef-
ﬁcacy than ketoprofen in this model of inﬂammation, accompanied
by a three-fold improvement in gastric tolerability. HCT 2037 con-
ﬁrms that CINODs provide improved GI safety while maintaining
full anti-inﬂammatory effects in animals. If conﬁrmed in humans,
CINODs may represent a valuable therapeutic option for arthritic
pathologies.
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ATTENUATION OF INFLAMMATORY EVENTS IN HUMAN
INTERVERTEBRAL DISC CELLS WITH A TUMOR NECROSIS
FACTOR ANTAGONIST
S.M. Sinclair1, L. Jing1, J. Chen1, W.J. Richardson2,
C.R. Brown2, R.D. Fitch2, L.A. Setton1,2
1Dept. of BioMed. Engineering, Duke Univ., Durham, NC; 2Dept.
of Surgery, Div. of Orthopaedic Surgery, Duke Univ., Durham, NC
Purpose: Pathologic intervertebral disc (IVD) tissues contain
some macrophages and lymphocytes, as well as their proinﬂam-
matory cytokine products including TNFα, IL-1β, IL-8 and IFNγ.
TNFα is believed to be a key mediator of inﬂammation in multiple
IVD pathologies, with clinical interest in the delivery of TNF antag-
onists as therapeutic agents for attenuating symptoms of sciatica.
Soluble TNF receptors are potent TNF antagonists, capable of
high afﬁnity binding to TNFα thereby sequestering the cytokine
from cell receptors and downstream effects. Here, we characterize
the inﬂammatory phenotype of primary human IVD cells following
TNFα stimulation in vitro, and measure the potential antagonistic
activity of soluble TNF receptor II (sTNFRII).
Methods: Human IVD cells were isolated from to-be discarded
surgical tissues from patients undergoing surgery for degenerative
IVD pathology (n=11, age: 14 - 81yr). Human IVD cells were
seeded (50,000 cells/well, 48-well plates) in 300μl culture media
supplemented with 25 ng/ml rhTNFα (Abcam) and 10% FBS for
72 hrs; control cells received no TNFα. Four groups received a
dose of sTNFRII (12.5-100nM, Abcam) in addition to TNFα for
the 72h period. All supernatants were assayed for release of
nitric oxide (NO, n=11; Greiss reaction), and a subset of samples
were assayed for production of IL-6 and PGE2 (n=4; ELISA, R&D
Systems). All values were determined as differences from culture
media-only values at 72h, and normalized by control values for
cultures in the absence of TNFα to quantify the level of TNFα-
induction. Dose-dependent attenuation of TNFα-induction of NO,
PGE2 or IL-6 was then quantiﬁed by determining a 50% inhibitory
concentration (IC50). Statistical signiﬁcance was evaluated with
one-way ANOVA and a post-hoc Tukey’s HSD test.
Results: Pathologic IVD cells in the presence of TNFα exhibited
an inﬂammatory phenotype characterized by an average increased
production of NO (3-fold over control values of 11.0±2.73 μM),
PGE2 (67-fold over control of 188±245 pg/ml) and IL-6 (3-fold
over control of 703±421 pg/ml). These cellular responses to
TNFα are consistent with values reported previously for human
nucleus pulposus cells. Responses to TNFα were characterized by
signiﬁcant patient-to-patient variability, however, with a very large
range of values for NO, PGE2, and IL-6 quantiﬁed in supernatants.
Cells receiving a dose of sTNFRII exhibited some attenuation
of TNFα-induced responses, although the patient-variability was
signiﬁcant as for treatment with TNFα alone. sTNFRII attenuation
of TNFα effects followed a typical dose-dependent response in
IVD cells for measures of NO and PGE2 production, with IC50
values measured to be 29nM and 86nM, respectively.
Conclusions: These data conﬁrm previous reports of statistically
signiﬁcant increases in TNFα-induced release of NO, PGE2, and
IL-6 by human IVD cells and demonstrate that targeting TNFα
activity can attenuate the TNFα-induced upregulation of inﬂamma-
tory events of IVD cells These data point to a need for further
study of sTNFRII as a therapeutic candidate for treatment of IVD
pathologies, and support the current clinical interest in treating
sciatica with commercially available receptor analogues.
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PHARMACEUTICAL COST IN PATIENTS WITH KNEE
OSTEOARTHRITIS
M. Acasuso-Diaz1, J. Vidal-Lorenzo2
1Hosp. Modelo, SAP San Jose, A Coruña, Spain; 2SAP San Jose,
A Coruña, Spain
Purpose: Knee osteoarthritis is a frequent cause of joint pain and
is estimated to be the most common cause of painful knee in
adults.It is very frequent in the Spanish population. According to
the EPISER study, performed by the Spanish Society of Rheuma-
tology, 29% of the Spanish population over age 60 showed symp-
tomatic knee osteoarthritis (KOA). The goals of management of
patients with knee osteoarthritis are to control pain, minimize dis-
ability, improve the quality of life, and educate the patient about
his or her role in the management team. The aim of this study
was to assess the pharmacological cost generated by a group of
patients diagnosed with knee osteoarthritis.
Methods: This is a transversal descriptive study performed in
2008. The study included 188 patients both male and female
over age 40, diagnosed with knee arthrosis (KOA) according to
ACR diagnostic criteria. Patients were collected from the OMI-AP
program database. This study analyzed the total number of drug
packs consumed per year per patient with KOA. The average cost
of each medication and the annual cost were then calculated. The
cost per patient per year was obtained as the total cost and total
number of patients ratio.
Results: Seventy-eight percent (78%) of patients included in the
study were female and 26% were male (3,5:1). The average age
was 69,22 years (DE ±9,29) and 56% of patients were older than
70 years and. Sixty-seven percent (67%) of the patients showed
bilateral KOA, 18% showed right knee involvement and 15% left
knee involvement.
NSAID were the most frequent prescribed drug to treat KOA
(36%) followed by SYSADOAs (17%), Paracetamol 1g. (14%),
topical treatments (13%), other painkillers such as metamizol,
opioids and tramadol (10%), and gastric protectors (10%). From
all NSAIDS, Diclofenac was the most frequent prescribed drug
(72 %) and Glucosamine Sulfate was the most frequent pre-
scribed SYSADOAs (65%). Chondrotin Sulfate and Diacerheine
represented 21% and 14% respectively.
From all prescribed drugs the highest spending was due to NSAIDs
administration (35%), followed by SYSADOAs (27%), painkillers
other than Paracetamol (18%), Paracetamol 1g. (8%) and topical
and IBP 6% each. Interestedly, although COXIB drugs repre-
